MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Inhaltsverzeichnis

Für die aktuelle Seite ist keine Übersetzung verfügbar, daher wurde sie in der Standardsprache dargestellt.

.. 0 Table of Contents
... 1 Home
... 2 Guidance
.... 2.1 Guidance for Researchers
.... 2.2 Guidance for Implementers
.... 2.3 UML Diagrams
.... 2.4 Application Scenarios
.... 2.5 DNPM Transformation
.... 2.6 Panel Catalog
... 3 Security and Privacy
... 4 Profiles
... 5 Extensions
... 6 Capability Statements
... 7 Logical Models
... 8 Value Sets
... 9 Code Systems
... 10 Examples
... 11 Downloads
... 12 Changelog
... 13 Metadata Overview
... 14 Versioning
... 15 MII ImplementationGuide Resource
... 16 Translation Information
... 17 Artifacts Summary
.... 17.1 MII CPS MTB CapabilityStatement
.... 17.2 DNPM MTB Care Plan
.... 17.3 DNPM NGS Report
.... 17.4 DNPM Patient Record
.... 17.5 MII LM Molekulares Tumorboard
.... 17.6 Genomic Study Device
.... 17.7 MII PR Biomarker Her2 Status
.... 17.8 MII PR MTB Antrag Kostenuebernahme
.... 17.9 MII PR MTB Anwort Kostenuebernahme
.... 17.10 MII PR MTB Behandlungsepisode
.... 17.11 MII PR MTB Biopsie Auftrag
.... 17.12 MII PR MTB BRCAness
.... 17.13 MII PR MTB Clinical Impresssion
.... 17.14 MII PR MTB Consent
.... 17.15 MII PR MTB Copy Number Variant
.... 17.16 MII PR MTB Diagnose Primärtumor
.... 17.17 MII PR MTB Diagnostische Implikation
.... 17.18 MII PR MTB DNA Fusion
.... 17.19 MII PR MTB Einfache Variante
.... 17.20 MII PR MTB Genomic Study
.... 17.21 MII PR MTB Genomic Study Analysis
.... 17.22 MII PR MTB Histologie-Evaluation Auftrag
.... 17.23 MII PR MTB HRD Score
.... 17.24 MII PR MTB Human-genetische Beratung Auftrag
.... 17.25 MII PR MTB Immunohistochemistry
.... 17.26 MII PR MTB Immunohistochemistry
.... 17.27 MII PR MTB Immunohistochemistry
.... 17.28 MII PR MTB Immunohistochemistry Microsatellite Instability
.... 17.29 MII PR MTB Immunohistochemistry Mismatch Repair Status
.... 17.30 MII PR MTB Immunohistochemistry Phosphorylation
.... 17.31 MII PR MTB In Situ Hybridization
.... 17.32 MII PR MTB In Situ Hybridization HER2
.... 17.33 MII PR MTB Mikrosatelliteninstabilität
.... 17.34 MII PR MTB Molecular Pathology Report
.... 17.35 MII PR MTB Molekularer Biomarker
.... 17.36 MII PR MTB Mutationslast
.... 17.37 MII PR MTB NGS-Bericht
.... 17.38 MII PR MTB Oncotree Klassifikation
.... 17.39 MII PR MTB Panel DeviceDefinition
.... 17.40 MII PR MTB Ploidie
.... 17.41 MII PR MTB Response Befund
.... 17.42 MII PR MTB RNA Fusion
.... 17.43 MII PR MTB RNA Seq
.... 17.44 MII PR MTB Studie
.... 17.45 MII PR MTB Studieneinschluss Anfrage
.... 17.46 MII PR MTB Systemische Therapie
.... 17.47 MII PR MTB Systemische Vortherapie
.... 17.48 MII PR MTB Systemtherapie Medication Statement
.... 17.49 MII PR MTB Therapeutische Implikation
.... 17.50 MII PR MTB Therapieempfehlung Kombinationstherapie
.... 17.51 MII PR MTB Therapieempfehlung Systemische Therapie
.... 17.52 MII PR MTB Therapieplan
.... 17.53 MII PR MTB Tumorausbreitung
.... 17.54 MII PR MTB Tumorzellgehalt
.... 17.55 MII PR MTB WHO Grad Tumor ZNS
.... 17.56 MII EX MTB Antrag GenomicsStudyAnalysis Metrics
.... 17.57 MII EX MTB Antrag Kostenuebernahme Antragsstadium
.... 17.58 MII EX MTB Antwort Kostenuebernahme Ablehnungsgrund
.... 17.59 MII EX MTB Antwort Kostenuebernahme Entscheidung
.... 17.60 MII EX MTB Diagnose
.... 17.61 MII EX MTB Empfehlung Evidenzgraduierung
.... 17.62 MII EX MTB Empfehlung Priorität
.... 17.63 MII EX MTB Empfehlung Publikation
.... 17.64 MII EX MTB Leitlinie Dokumentation
.... 17.65 MII EX MTB Leitlinienbehandlung Status
.... 17.66 MII EX MTB NGS Bericht Metadaten
.... 17.67 MII EX MTB Panel Gene List
.... 17.68 MII VS Antrag Kostenuebernahme Antragsstadium
.... 17.69 MII VS Antwort Kostenuebernahme Entscheidung
.... 17.70 MII VS Auftrag Begründung
.... 17.71 MII VS Bestimmungsmethode Tumorzellgehalt
.... 17.72 MII VS Dosisdichte
.... 17.73 MII VS Empfehlung Evidenzgrad
.... 17.74 MII VS Empfehlung Evidenzgrad Zusatzverweis
.... 17.75 MII VS Empfehlung Status Begründung
.... 17.76 MII VS Follow-Up Grund Nicht-Umsetzung
.... 17.77 MII VS Follow-Up Status
.... 17.78 MII VS Genomic Analysis Method Type
.... 17.79 MII VS Kostenuebernahme Ablehnungsgrund
.... 17.80 MII VS Leitlinienbehandlung Status
.... 17.81 MII VS Mikrosatelliteninstabilität
.... 17.82 MII VS Mismatch Repair Protein Proficiency
.... 17.83 MII VS Mismatch Repair Proteins Expression
.... 17.84 MII VS Molekulare Biomarker
.... 17.85 MII VS MSI Method Type
.... 17.86 MII VS MTB Antrag Kostenuebernahme
.... 17.87 MII VS MTB Immunhistochemistry Specific Codes
.... 17.88 MII VS MTB Interpretation High/Low
.... 17.89 MII VS MTB ISH Method
.... 17.90 MII VS MTB Panel Archer
.... 17.91 MII VS MTB Panel Basic-NGS
.... 17.92 MII VS MTB Panel Capability
.... 17.93 MII VS MTB Panel CGP
.... 17.94 MII VS MTB Panel DHS-3501Z
.... 17.95 MII VS MTB Panel OFA
.... 17.96 MII VS MTB Panel OFA plus
.... 17.97 MII VS MTB Panel TCM NGS
.... 17.98 MII VS MTB Panel TSO 500 Fusions
.... 17.99 MII VS MTB Panel TSO 500 SNVs
.... 17.100 MII VS MTB Systemtherapie Status
.... 17.101 MII VS OncoTree ValueSet
.... 17.102 MII VS Response Befund Beurteilung
.... 17.103 MII VS Response Befund Beurteilung
.... 17.104 MII VS Therapiestatusgrund
.... 17.105 MII VS Tumorausbreitung
.... 17.106 MII VS WHO Grad Tumor ZNS
.... 17.107 MII VS Zulassungsstatus
.... 17.108 MII CS Antrag Kostenuebernahme Antragsstadium
.... 17.109 MII CS Antwort Kostenuebernahme Entscheidung
.... 17.110 MII CS Bestimmungsmethode Tumorzellgehalt
.... 17.111 MII CS Dosisdichte
.... 17.112 MII CS Empfehlung Evidenzgrad
.... 17.113 MII CS Empfehlung Evidenzgrad Zusatzverweis
.... 17.114 MII CS Empfehlung Status Begründung
.... 17.115 MII CS Follow-Up Status
.... 17.116 MII CS Genomic Analysis Method Type
.... 17.117 MII CS GenomicAnalysis DeviceType
.... 17.118 MII CS Human-genetische Beratung Auftrag Begründung
.... 17.119 MII CS Kostenuebernahme Ablehnungsgrund
.... 17.120 MII CS Leitlinienbehandlung Status
.... 17.121 MII CS Molekulare Biomarker
.... 17.122 MII CS MSI Method Type
.... 17.123 MII CS MTB Panel Capability
.... 17.124 MII CS Response Befund Beurteilung
.... 17.125 MII CS Response Befund Beurteilungsmethode
.... 17.126 MII CS Therapiestatusgrund
.... 17.127 MII CS Zulassungsstatus
.... 17.128 MII NS MTB NCT
.... 17.129 MII NS Studie DRKS
.... 17.130 MII NS Studie EudraCT
.... 17.131 MII CM MTB Therapiestatusgrund oBDS Mapping
.... 17.132 MII CM MTB Therapiestatusgrund SNOMED CT Mapping
.... 17.133 01.05.2023 Krankenkassenantrag Mirvetuximab soravtansine genehmigt
.... 17.134 07.08.2023 Z3 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22
.... 17.135 10.03.2023 Krankenkassenantrag gestellt Mirvetuximab soravtansine
.... 17.136 12.10.2023 Z6 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22
.... 17.137 16.07.2023 Z2 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22
.... 17.138 20.08.2023 CT T/A
.... 17.139 20.09.2023 Z5 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22
.... 17.140 22.10.2023 CT T/A
.... 17.141 24.06.2023 - 12.10.2023 Mirvetuximab soravtansine
.... 17.142 24.06.2023 Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22
.... 17.143 24.06.2023 Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22
.... 17.144 29.08.2023 Z4 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22
.... 17.145 A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
.... 17.146 Adavosertib
.... 17.147 Adavosertib +/- Carboplatin
.... 17.148 Beispiel DNA-Fusion
.... 17.149 Beispiel fuer BRAF Mutation MTB Diagnostische Implikation
.... 17.150 Beispiel fuer BRCAness-Analyse
.... 17.151 Beispiel fuer Copy Number Variant
.... 17.152 Beispiel fuer eine Antwort auf den Antrag auf Kostenuebernahme
.... 17.153 Beispiel fuer eine Follow-Up Clinical Impression
.... 17.154 Beispiel fuer eine Systemtherapie
.... 17.155 Beispiel fuer einen Antrag auf Kostenuebernahme
.... 17.156 Beispiel fuer einen GenomicStudy
.... 17.157 Beispiel fuer einen GenomicStudyAnalysis
.... 17.158 Beispiel fuer einen Response Befund
.... 17.159 Beispiel fuer einen Sequencer
.... 17.160 Beispiel für ein Library Preparation Kit
.... 17.161 Beispiel für ein SequencingKit
.... 17.162 Beispiel HRD-Score
.... 17.163 Beispiel Mikrosatelliteninstabilität
.... 17.164 Beispiel Mutationslast in Tumorprobe (MTB)
.... 17.165 Beispiel RNA-Fusion
.... 17.166 Beispiel-Probe (Tumorgewebe)
.... 17.167 Bestätigte Primärdiagnose
.... 17.168 BioNTech Cell & Gene Therapies GmbH
.... 17.169 BioNTech Responsible Person
.... 17.170 BRAF Variante
.... 17.171 CA 125 Tumor Marker Observation 1
.... 17.172 CA 125 Tumor Marker Observation 2
.... 17.173 CA 125 Tumor Marker Observation 3
.... 17.174 CA 125 Tumor Marker Observation 4
.... 17.175 CA 125 Tumor Marker Observation 5
.... 17.176 CA 125 Tumor Marker Observation 6
.... 17.177 Camonsertib
.... 17.178 Carboplatin
.... 17.179 CCNE1
.... 17.180 CCNE1
.... 17.181 CCNE1 Einfache Variante 2
.... 17.182 Cobimetinib
.... 17.183 Einwilligung zur MTB-Besprechung Kim Musterperson
.... 17.184 Empfehlung Biopsie
.... 17.185 Empfehlung Histologie-Evaluation
.... 17.186 Empfehlung Human-genetische Beratung
.... 17.187 Example In Situ Hybridization HER2/ERBB2
.... 17.188 Follow-Up Prozess zur Überprüfung der durchgeführten Therapien & Kostenübernahmen
.... 17.189 High-Grade Neuroendocrine Carcinoma of the Ovary
.... 17.190 Lokale Tumorausbreitung
.... 17.191 Lunresertib
.... 17.192 Lunresertib + Camonsertib
.... 17.193 MII PR MTB Behandlungsepisode Beispiel
.... 17.194 MII PR MTB WHO Grad Tumor ZNS
.... 17.195 mii-exa-mtb-kim-musterperson-bundle
.... 17.196 mii-exa-mtb-patient
.... 17.197 mii-exa-mtb-therapieempfehlung-dabrafenib
.... 17.198 mii-exa-mtb-therapieempfehlung-kombinationstherapie
.... 17.199 mii-exa-mtb-therapieempfehlung-trametinib
.... 17.200 mii-exa-mtb-therapieplan-kombinationstherapie
.... 17.201 mii-exa-onko-allgemeiner-leistungszustand-ecog
.... 17.202 Mirvetuximab soravtansine
.... 17.203 MTB-Behandlungsepisode Kim Musterperson
.... 17.204 MTB-Beschluss Kim Musterperson
.... 17.205 MTB-NGS-Bericht Kim Musterperson
.... 17.206 MTB-NGS-Bericht Kim Musterperson
.... 17.207 MTB-NGS-Bericht Kim Musterperson
.... 17.208 MTB-NGS-Bericht Kim Musterperson
.... 17.209 MTB-NGS-Bericht Kim Musterperson HLA Status
.... 17.210 MTBChemo1MedicationStatement1
.... 17.211 MTBChemo1MedicationStatement1-1
.... 17.212 MTBChemo1MedicationStatement1-2
.... 17.213 MTBChemo1MedicationStatement2
.... 17.214 MTBChemo1MedicationStatement2-1
.... 17.215 MTBChemo1MedicationStatement2-2
.... 17.216 MTBChemo1MedicationStatement3
.... 17.217 MTBChemo1MedicationStatement3-1
.... 17.218 MTBChemo1MedicationStatement3-2
.... 17.219 MTBChemo1MedicationStatement4
.... 17.220 MTBChemo1MedicationStatement4-1
.... 17.221 MTBChemo1MedicationStatement4-2
.... 17.222 MTBChemo1MedicationStatement5
.... 17.223 MTBChemo1MedicationStatement5-1
.... 17.224 MTBChemo1MedicationStatement5-2
.... 17.225 MTBChemo1MedicationStatement6
.... 17.226 MTBChemo1MedicationStatement6-1
.... 17.227 MTBChemo1MedicationStatement6-2
.... 17.228 MTBChemo1Procedure
.... 17.229 MTBChemo2MedicationStatement1
.... 17.230 MTBChemo2MedicationStatement2
.... 17.231 MTBChemo2MedicationStatement3
.... 17.232 MTBChemo2MedicationStatement4
.... 17.233 MTBChemo2MedicationStatement5
.... 17.234 MTBChemo2MedicationStatement6
.... 17.235 MTBChemo2Procedure
.... 17.236 MyCoverage
.... 17.237 MyHospital
.... 17.238 MyInsurer
.... 17.239 NCT04503278 Age Group
.... 17.240 NCT04503278 CLDN6 CAR-T
.... 17.241 NCT04503278 CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
.... 17.242 NCT04503278 Comparison Group: Part 1 - CLDN6 CAR-T
.... 17.243 NCT04503278 Comparison Group: Part 2 Vaccine-modulated - CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
.... 17.244 NCT04503278 Eligibility Criteria
.... 17.245 NCT04503278 L0
.... 17.246 NCT04503278 L1
.... 17.247 NCT04503278 L10
.... 17.248 NCT04503278 L11
.... 17.249 NCT04503278 L2
.... 17.250 NCT04503278 L3
.... 17.251 NCT04503278 L4
.... 17.252 NCT04503278 L5
.... 17.253 NCT04503278 L6
.... 17.254 NCT04503278 L7
.... 17.255 NCT04503278 L8
.... 17.256 NCT04503278 L9
.... 17.257 PatientKimMusterperson
.... 17.258 PatientKimMusterperson-AscitesSpecimen-2
.... 17.259 PatientKimMusterperson-MolecularPathologyInterpret-0a-Her2neu
.... 17.260 PatientKimMusterperson-MolecularPathologyObservation-0a-Her2neu
.... 17.261 PatientKimMusterperson-MolecularPathologyObservation-0b-Folat-Ra
.... 17.262 PatientKimMusterperson-MolecularPathologyObservation-0c-Trop2
.... 17.263 PatientKimMusterperson-MolecularPathologyObservation-1-CA125
.... 17.264 PatientKimMusterperson-MolecularPathologyObservation-2-Pax8
.... 17.265 PatientKimMusterperson-MolecularPathologyObservation-3-WT1
.... 17.266 PatientKimMusterperson-MolecularPathologyObservation-4-ER
.... 17.267 PatientKimMusterperson-MolecularPathologyObservation-5-PR
.... 17.268 PatientKimMusterperson-MolecularPathologyObservation-6-p53
.... 17.269 PatientKimMusterperson-MolecularPathologyObservation-7-p53
.... 17.270 PatientKimMusterperson-MolecularPathologyReport-1
.... 17.271 PatientKimMusterperson-Observation-1
.... 17.272 PatientKimMusterperson-Observation-10
.... 17.273 PatientKimMusterperson-Observation-11
.... 17.274 PatientKimMusterperson-Observation-12
.... 17.275 PatientKimMusterperson-Observation-13
.... 17.276 PatientKimMusterperson-Observation-14
.... 17.277 PatientKimMusterperson-Observation-15
.... 17.278 PatientKimMusterperson-Observation-16
.... 17.279 PatientKimMusterperson-Observation-17
.... 17.280 PatientKimMusterperson-Observation-18
.... 17.281 PatientKimMusterperson-Observation-19
.... 17.282 PatientKimMusterperson-Observation-2
.... 17.283 PatientKimMusterperson-Observation-20
.... 17.284 PatientKimMusterperson-Observation-21
.... 17.285 PatientKimMusterperson-Observation-22
.... 17.286 PatientKimMusterperson-Observation-23
.... 17.287 PatientKimMusterperson-Observation-24
.... 17.288 PatientKimMusterperson-Observation-25
.... 17.289 PatientKimMusterperson-Observation-26
.... 17.290 PatientKimMusterperson-Observation-27
.... 17.291 PatientKimMusterperson-Observation-29
.... 17.292 PatientKimMusterperson-Observation-3
.... 17.293 PatientKimMusterperson-Observation-30
.... 17.294 PatientKimMusterperson-Observation-4
.... 17.295 PatientKimMusterperson-Observation-5
.... 17.296 PatientKimMusterperson-Observation-6
.... 17.297 PatientKimMusterperson-Observation-7
.... 17.298 PatientKimMusterperson-Observation-8
.... 17.299 PatientKimMusterperson-Observation-9
.... 17.300 PatientKimMusterperson-PrimaryDiagnosis-2
.... 17.301 PatientKimMusterperson-Procedure-1
.... 17.302 PatientKimMusterperson-Procedure-2
.... 17.303 PatientKimMusterperson-Procedure-3
.... 17.304 PatientKimMusterperson-Procedure-4
.... 17.305 PatientKimMusterperson-Procedure-4a
.... 17.306 PatientKimMusterperson-Procedure-4b
.... 17.307 PatientKimMusterperson-Procedure-4c
.... 17.308 PatientKimMusterperson-Procedure-4d
.... 17.309 PatientKimMusterperson-Procedure-5
.... 17.310 PatientKimMusterperson-Procedure-6
.... 17.311 PatientKimMusterperson-Procedure-7
.... 17.312 PatientKimMusterperson-Specimen-1
.... 17.313 PatientKimMusterperson-SystemicTherapy-1
.... 17.314 PatientKimMusterperson-SystemicTherapy-2
.... 17.315 PatientKimMusterperson-SystemicTherapy-3
.... 17.316 Phase 1/2 CLDN6 CAR-T-Zell-Studie
.... 17.317 PIK3R1 Einfache Variante
.... 17.318 PIK3R1 Therapeutische Implikation
.... 17.319 Ploidie Beispiel
.... 17.320 TEDOVA
.... 17.321 TEDOVA
.... 17.322 TP53 Diagnostische Implikation
.... 17.323 TP53 Einfache Variante
.... 17.324 Trastuzumab deruxtecan
.... 17.325 Tumorzellgehalt Aszites
.... 17.326 Basic-NGS Panel
.... 17.327 DKTK/MASTER Whole-Genome/-Exome Sequencing
.... 17.328 FusionPlex Archer Lung V2
.... 17.329 MH IVD 600+
.... 17.330 mii-param-mtb-manifest
.... 17.331 Oncomine Focus Assay
.... 17.332 Oncomine Focus Assay Plus
.... 17.333 Qiagen DHS-3501Z
.... 17.334 SureSelect Cancer CGP Assay
.... 17.335 TCM NGS Panel
.... 17.336 TruSight Oncology 500
.... 17.337 Whole Genome Sequencing (generisch)